Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19592079 | 0.86 | ROCK2 (0.63) | ROCK2ROCK1EGFRRAB9A | |
| SCHEMBL19592109 | 0.82 | ROCK2 (0.64) | ROCK2ROCK1EGFR | |
| SCHEMBL18792356 | 0.81 | ROCK2 (0.66) | ROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL17038112 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL19592087 | 0.79 | ROCK2 (0.68) | ROCK2ROCK1FKBP1AMAPTEGFR | |
| SCHEMBL19591992 | 0.77 | ROCK2 (0.64) | ROCK2ROCK1EGFR | |
| SCHEMBL18792298 | 0.73 | ROCK2 (0.68) | ROCK2ROCK1KMT2ASMN1; SMN2 | |
| SCHEMBL19592078 | 0.73 | ROCK2 (0.66) | ROCK2ROCK1 | |
| SCHEMBL27249103 | 0.71 | ROCK2 (0.57) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL19592018 | 0.71 | ROCK2 (0.63) | ROCK2ROCK1KMT2AMAPTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147391-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION LLC | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147391-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885KMT2A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.